✦ LIBER ✦

Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer

✍ Scribed by Suresh Ramalingam; Michael C. Perry; Renato V. La Rocca; David Rinaldi; Preston S. Gable; William J. Tester; Chandra P. Belani

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 84 KB
Volume: 113
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.23583

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The impact of age on toxicity, response

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel

✍ Thomas A. Hensing; Amy H. Peterman; Michael J. Schell; Ji-Hyun Lee; Mark A. Soci 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 1 views

## Abstract ## BACKGROUND The optimal treatment strategy for elderly patients with advanced nonsmall cell lung carcinoma has not been defined to date. The authors performed a retrospective analysis of a Phase III trial that treated patients who had Stage IIIB or IV nonsmall cell lung carcinoma wit

Weekly docetaxel versus docetaxel/gemcit

Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer : A randomized phase 3 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; David R. Spigel; Cindy Farley; Dianna L. Shipley; James D. B 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

## Abstract ## BACKGROUND. The aim of this study was to compare the efficacy of single‐agent weekly docetaxel with the combination of docetaxel and gemcitabine in elderly and/or poor performance status patients with advanced nonsmall cell lung cancer (NSCLC). ## METHODS. Previously untreated pat